Burmeister Jayme E, Miltersteiner Diego R, Campos Bruno M
Renal Medicine Unit, Medicine School, Universidade Luterana do Brasil (ULBRA), Canoas, Rio Grande do Sul, Brazil.
J Nephrol. 2009 Jan-Feb;22(1):83-9.
Patients on regular hemodialysis present high cardiovascular mortality. Uremic dyslipidemia and inflammation take part in the etiology of atherosclerosis. Rosuvastatin calcium has not been studied in patients on dialysis to date. We sought to evaluate the results of rosuvastatin therapy regarding lipids, lipoproteins and a marker of inflammation in hemodialysis patients.
In a double-blind randomized placebo-controlled trial, 59 patients on hemodialysis (31 in the placebo group, and 28 taking rosuvastatin 10 mg/day) were followed for 3 months. Lipids, lipoproteins and high-sensitivity C-reactive protein (hs-CRP) were measured at baseline, 30 days and 3 months.
In the rosuvastatin group, there was a significant decrease from baseline to the study end in total cholesterol (163+/-53 mg/dL to 142+/-43 mg/dL; p<0.05), in LDL cholesterol (90+/-39 mg/dL to 69+/-32 mg/dL; p<0.05) and in non-HDL cholesterol (121+/-46 mg/dL to 99+/-39 mg/dL; p<0.05). In the placebo group, no significant decrease was observed. High-sensitivity CRP was lower in the rosuvastatin than in the placebo group at 3 months (p<0.01).
Rosuvastatin calcium at 10 mg/day was effective in lowering total cholesterol, LDL cholesterol, non-HDL cholesterol and hs-CRP in hemodialysis patients.
接受常规血液透析的患者心血管死亡率较高。尿毒症血脂异常和炎症参与动脉粥样硬化的病因。迄今为止，尚未在透析患者中研究瑞舒伐他汀钙。我们试图评估瑞舒伐他汀治疗对血液透析患者血脂、脂蛋白和炎症标志物的影响。
在一项双盲随机安慰剂对照试验中，59例血液透析患者（31例在安慰剂组，28例服用瑞舒伐他汀10毫克/天）随访3个月。在基线、30天和3个月时测量血脂、脂蛋白和高敏C反应蛋白（hs-CRP）。
在瑞舒伐他汀组，从基线到研究结束时，总胆固醇（163±53毫克/分升降至142±43毫克/分升；p<0.05）、低密度脂蛋白胆固醇（90±39毫克/分升降至69±32毫克/分升；p<0.05）和非高密度脂蛋白胆固醇（121±46毫克/分升降至99±39毫克/分升；p<0.05）均有显著下降。在安慰剂组，未观察到显著下降。3个月时，瑞舒伐他汀组的高敏CRP低于安慰剂组（p<0.01）。
每天10毫克的瑞舒伐他汀钙对降低血液透析患者的总胆固醇、低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇和hs-CRP有效。
